VTYX vs. VRCA, KMDA, ORGO, CRMD, NLTX, VNDA, AVIR, URGN, NKTX, and PROC
Should you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Organogenesis (ORGO), CorMedix (CRMD), Neoleukin Therapeutics (NLTX), Vanda Pharmaceuticals (VNDA), Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Nkarta (NKTX), and Procaps Group (PROC). These companies are all part of the "pharmaceutical preparations" industry.
Verrica Pharmaceuticals (NASDAQ:VRCA) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.
Verrica Pharmaceuticals has higher revenue and earnings than Ventyx Biosciences. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 42.6% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 24.4% of Ventyx Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Verrica Pharmaceuticals had 9 more articles in the media than Ventyx Biosciences. MarketBeat recorded 17 mentions for Verrica Pharmaceuticals and 8 mentions for Ventyx Biosciences. Verrica Pharmaceuticals' average media sentiment score of 0.87 beat Ventyx Biosciences' score of 0.44 indicating that Ventyx Biosciences is being referred to more favorably in the news media.
Verrica Pharmaceuticals presently has a consensus price target of $13.50, indicating a potential upside of 24.54%. Ventyx Biosciences has a consensus price target of $21.75, indicating a potential upside of 401.15%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Ventyx Biosciences is more favorable than Verrica Pharmaceuticals.
Ventyx Biosciences has a net margin of 0.00% compared to Ventyx Biosciences' net margin of -1,307.47%. Verrica Pharmaceuticals' return on equity of -67.20% beat Ventyx Biosciences' return on equity.
Verrica Pharmaceuticals received 136 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 64.94% of users gave Verrica Pharmaceuticals an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
Summary
Verrica Pharmaceuticals beats Ventyx Biosciences on 9 of the 17 factors compared between the two stocks.
Get Ventyx Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ventyx Biosciences Competitors List
Related Companies and Tools
